A recent study reveals that individuals who discontinue new slimming jabs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Findings released in a prominent health publication demonstrates that while obese people can lose a large proportion of their body weight while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these treatments must be aware of the potential of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting weight within about 18 months.
Comparing Therapies
The research, which examined dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Researchers note that people who lose weight through dieting usually have a slower creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Regain
Experts suggest the mode of action of the drugs explains the amplified rebound.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, given the high risk of weight regain, the therapy might need to be life-long.
This opinion is echoed by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," similar to managing conditions like high blood pressure.
User Experiences
Individuals who have discontinued the medication explain a intense resurgence of hunger.
"I experienced something that goes on and I was suddenly starving," said a patient.
This difficulty is compounded if patients have not developed lasting lifestyle or habit modifications during treatment.
Significant Use
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is more common among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while the jabs are effective tools for weight loss, they are not a magic cure and maintained weight loss hinges on ongoing behavioural changes.
